and lymphatic channels leading to poor prognosis. 9 It is the only cancer where millimeters (not centimeters) of tumor are used in the staging system, with a 4 mm melanoma imparting as much risk as a 10 cm lung tumor. Furthermore, melanomas can downregulate patients' own intrinsic immune system pathways creating both a local and systemic immune-depleted state. 10 
Current Standard of Care
Three drugs have long been approved by the US Food and Drug Administration (FDA) for the treatment of metastatic melanoma:
hydroxyurea, dacarbazine and IL-2; hydroxyurea was approved in 1967
and is now rarely used as a treatment for melanoma. Dacarbazine gained approval for treating metastatic melanoma in the 1970s, but it has consistently failed to show a significant impact on survival in the last 40 years of use. 11 More recent studies place response rates of dacarbazine at the 5-10 % range with very few long-term survivors and with significant associated toxicities including nausea, vomiting and myelosuppression. [12] [13] [14] High-dose interleukin-2 (HD IL-2) was approved based on an analysis of pooled Phase II data showing an overall response rate of approximately 16 %. However, 6 % of treated patients are complete responders, most of which are durable with some patients surviving many years after receiving therapy. 15, 16 However, HD IL-2 must be administered in hospital by trained, experienced personnel owing to its toxicity profile and requires referral of patients into these centers. At present, use of IL-2 in the US is limited to specialist centers with the resources and expertise in managing administration of this drug regimen. Dacarbazine and its analog temozolomide 6 are likely the most frequently administered drugs in this country for metastatic melanoma despite no evidence of improved survival. Temozolomide is currently only approved for primary brain tumors. 17, 18 Other agents which have been employed include platinum, taxanes, vinblastine, interferon, and fotemustine, which is approved in Europe. 19 Combinations of these various agents has been disappointing to date in demonstrating either additive or synergistic effects. However, biochemotherapy is an aggressive treatment using three chemotherapeutic A second Phase III trial was performed evaluating ipilimumab together with dacarbazine. 13 A total of 502 patients with previously untreated metastatic melanoma were randomized in a 1:1 fashion to receive either the combination or dacarbazine alone. Here, a dose of 10 mg/kg of ipilimumab was administered with or without dacarbazine (850 mg/m 2 )
at weeks one, four, seve, and 10, followed by dacarbazine alone every three weeks until week 22. This study used a 10 mg/kg dose during the induction and maintenance phases because this level had been previously shown to provide significantly improved response rates over the 3 or 0.3 mg/kg dose levels (p=0.002). 28 It was found that ipilimumab plus dacarbazine improved OS in patients compared with dacarbazine alone and there were higher survival rates at years one, two, and three (HR for death: 0.72, p<0.001) but grade 3 or 4 adverse events were higher with the combined therapy.
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PD1 and PD1 Ligand
An anti-PD-1 monoclonal antibody treatment (BMS-936558, MDX-1106) that blocks the inhibitory action of PD-1 on T-cells is in clinical development for metastatic melanoma. This is a novel treatment that has raised much interest among oncologists and has much potential in the treatment of advanced melanoma. A diagrammatic scheme
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indicating the action of PD1/PD1-Ligand and CTLA-4 blockers on T-cell function is given in Figure 1 . A recent Phase I study investigated the use of BMS-936558 given at 1, 3, or 10 mg/kg doses combined with a multipeptide vaccine (MART-1/gp100/NY-ESO-1) in patients with stage IV melanoma who had previously received treatment. 29 The results show that the 1 and 3 mg/kg dose levels were well tolerated; the 10 mg/kg dose part of the study is ongoing. Responses were seen at all dose levels and PD-1 levels on T-cells decreased but CTLA-4 levels increased in CD4 T-cells in all dose groups. There was a dose-related decrease in CD8 T-cells and in viral-specific T-cells. It was concluded that further work was needed to determine the optimal dose. Interim results were recently published from an ongoing larger clinical trial of BMS-936558. 30 These showed that 95 patients with advanced melanoma had been treated and there was an objective response in 20 patients. To date in this study, BMS-936558 has produced a durable clinical benefit in patients with advanced melanoma, including those who had received previous immunotherapy. Further results from this trial on a larger group of patients are awaited.
Targeted Agents
Mitogen-activated protein kinase (MAPK) pathways are a set of signaling mechanisms that regulate a diverse range of cellular functions including differentiation, proliferation and apoptosis. In melanomas and other tumor tissues, the discovery of a series of mutations in genes encoding kinases involved in these pathways led to various new anti-cancer treatments that exploit these as targets for treatment.
Faulty activation of the MAPK pathway has been reported over 80 % of cutaneous melanomas due to abnormalities at various points in the RAS-RAF-MEK-ERK pathway. 31 Among the mutations in the MAPK pathways, those of a serine/threonine protein kinase (BRAF) are the most extensively studied. These mutations are found in 35-59 % of primary melanomas and 42-66 % of metastatic melanomas and have been found in human skin sites after exposure to the sun. [32] [33] [34] Other genetic changes associated with melanoma include high cyclin (CCND1) and cyclin-dependent kinase (CKD4) copy numbers. 35 Increased copy numbers of some scaffold protein GAB2 and mutation in the CKIT and NRAS are also strongly correlated with melanoma.
36,37
Vemurafenib Vemurafenib is a highly specific BRAF inhibitor that targets the BRAF V600E mutation which is found in approximately 50 % of patients with melanoma. 38 In BRAF-mutated tumors, signaling through the MAPK pathway is constitutively activated which leads to increased growth of melanoma cells, greater ability of malignant cells to spread throughout the body, and increased blood vessel formation around the tumor.
A pivotal Phase I trial showed that 81 % of patients with detectable BRAF V600E mutations in their tumor have treatment response to vemurafenib. While most patients will have a dramatic reduction in their tumors within weeks of initiating therapy, patients will likely progress after approximately seven months of treatment. 39 These results were confirmed in a Phase II trial 40 in which the overall response rate was 53 %, median OS and PFS were 15.9 and 6.8 months, respectively. Re-analysis of the response rate in the Phase 1 study according to the response criteria used in the Phase 2 study yielded a similar overall response rate of 56 %.
The Phase III trial (BRAF Inhibitor in Melanoma; BRIM-3) of vemurafenib versus dacarbazine accrued 675 patients very quickly and was found to demonstrate a statistically significant benefit at the first interim analysis leading the Data Safety Monitoring Board to recommend that patients randomized to dacarbazine be allowed to crossover to vemurafenib. 12 The data generated by this trial eventually led to the approval of vemurafenib. At six months, OS was 84 % in the vemurafenib group and 64 % in the dacarbazine group with response rates of 48 and 5 %, respectively. Common side effects associated with vemurafenib included arthralgia, rash, fatigue, alopecia, photosensitivity, nausea, and diarrhea. 12 Updated results from the BRIM-3 study after median lengths of follow-up on vemurafenib and dacarbazine of 10.5 months and 8.4 months, showed that median OS times with vemurafenib and dacarbazine were 13.2 months and 9.6 months and 12-month OS rates were 55 and 43 %, respectively. The expression of splicing isoforms of BRAF(V600E) that dimerize in a RAS-independent manner was also detected and is possibly a novel mechanism of acquired resistance in melanoma patients. 
MEK inhibitors
A series of MEK inhibitors are currently in development, several of them for the treatment of melanoma. The furthest in development is trametinib (GSK 1120212). In the ongoing METRIC Phase III study, patients with metastatic melanoma who were BRAF V600E/K were randomized to trametinib (n=210) or a comparator treatment (dacarbazine or paclitaxel) over an 8-month period. 46 The PFS times for trametinib and comparator treatments were 4.8 months versus mutations were treated with imatinib 400 mg/day. 49 The median PFS was 3.5 months, the six-month PFS rate was 36.6 % and the rate of total disease control was 53.5 %. In the study, the overall response rate Further work is required to evaluate the CKIT mutations as targets in melanoma but early results show promise.
Strategies for Improving Outcomes in the Treatment of Metastatic Melanoma
While there is currently little consensus regarding optimal therapy for metastatic melanoma, several general recommendations can be made;
in particular, BRAF mutational status should be determined on all patients at diagnosis in order to determine potential options. Likewise, CKIT mutations should be analyzed especially in acral lentiginous melanoma or melanoma arising in chronically sun-damaged skin. BRAF mutations in melanoma can be atypical and heterogeneous, even in different tumors from the same patient. Reliably detecting and monitoring these mutations can be challenging. The optimal method to detect BRAF mutations remains unclear due to differences is sensitivity and specificity. 51 In one study that analyzed melanoma tissues taken from patients, different methodologies were compared. Mutations were detected in 32 % of melanomas using direct sequencing but they were detected in 76 % of melanomas using mutant-specific PCR. 52 In a subgroup that was further analyzed, six of nine tumors, showed differing proportions of BRAFV600E and BRAF wild-type cells in separate microdissected tumor regions. Repeated analyses of tumor samples from a group of individual patients using a highly sensitive mutant-specific PCR technique showed that 26 % patients had metastases that were discordant for the BRAFV600 mutation. In light of these results, the authors urged that further studies should be initiated to determine what effect BRAF mutational heterogeneity within and between tumors has on eventual clinical outcomes.
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Predictors of Response
Clinical measures such as pretreatment lactate dehydrogenase, performance status and the presence of visceral versus non-visceral metastases may be useful in distinguishing likely responders. Much research has attempted to further define the patients most likely to benefit from immunotherapy. 53 Indeed, a clinical trial testing the utility of proposed predictors is ongoing. 54 Certain mutations may play a role in disease susceptibility to immunotherapy as NRAS-mutated patients appear to have increased response rates to HD IL-2. It is our practice to obtain BRAF mutational status on all patients with advanced melanoma. CKIT mutation status can also be considered in patients with acral lentininous or mucosal melanomas or in patients with chronic sun damaged skin. NRAS mutational testing should also be considered as research is ongoing in finding agents effective in NRAS-mutated disease. Table 1 lists the approximate prevalence of the more common mutations observed in metastatic melanoma.
Design and Findings of Ongoing Studies
In patients whose melanomas are symptomatic and harbor a BRAF mutation, a BRAF-directed therapy should be used preferentially as symptom management is most rapid from this treatment approach. 
Combination and Sequential Therapies
Novel combination approaches have been investigated in recent years. The National Cancer Institute combined HD IL-2 with ipilimumab in a Phase I/II trial of 32 patients which showed no added toxicity and a 22 % overall response rate, with 8 % experiencing a CR. 55 The dose combination employed in the Phase II portion used 3 mg/kg ipilimumab at three-week intervals with a standard cycle of HD IL-2 during the second and third doses of ipilimumab. A follow-up report showed 17 % of patients alive and disease-free with a median follow-up of >6 years.
Two additional patients in this group were put into a sustained CR by tumor-infiltrating lymphocyte therapy 56 Ipilimumab plus bevacizumab has been evaluated in a Phase I trial for metastatic melanoma;
response rates appeared to be superior to that of ipilimumab alone with negligible toxicity. 57 Both ipilimumab and HD IL-2 have been assessed in conjunction with the peptide vaccine gp100 in controlled trials. Interestingly, the gp100 vaccine arm did better when it was combined with HD IL-2 59 and fared worse when it was combined with ipilimumab 28 The side effects of the different agents used in melanoma are fairly well known and it is anticipated that they can largely be managed in combinations.
Summary and Conclusions
Metastatic melanoma remains a challenge for oncologists. However, with the advent of multiple new agents, there is now the potential for much improved outcomes. The current advances in this field hold the promise of more patients in the future experiencing long-term complete responses.
Better understanding of the disease biology and drug mechanisms will allow for optimal benefits from combinations and sequences of agents with the ultimate goal of curing this disease. n 
